Mizuho Maintains Buy on Ventas, Lowers Price Target to $61
Mizuho analyst Vikram Malhorta maintains Ventas (NYSE:VTR) with a Buy and lowers the price target from $65 to $61.
Mizuho Maintains Buy on Welltower OP, Lowers Price Target to $93
Mizuho analyst Vikram Malhorta maintains Welltower OP (NYSE:WELL) with a Buy and lowers the price target from $96 to $93.
Mizuho Maintains Buy on Universal Health Services, Lowers Price Target to $121
Mizuho analyst Ann Hynes maintains Universal Health Services (NYSE:UHS) with a Buy and lowers the price target from $153 to $121.
Goldman Sachs Maintains Buy on Iovance Biotherapeutics, Lowers Price Target to $18
Goldman Sachs analyst Madhu Kumar maintains Iovance Biotherapeutics (NASDAQ:IOVA) with a Buy and lowers the price target from $64 to $18.
Mizuho Maintains Buy on Tenet Healthcare, Lowers Price Target to $63
Mizuho analyst Ann Hynes maintains Tenet Healthcare (NYSE:THC) with a Buy and lowers the price target from $103 to $63.
RBC Capital Maintains Sector Perform on Wells Fargo, Lowers Price Target to $45
RBC Capital analyst Gerard Cassidy maintains Wells Fargo (NYSE:WFC) with a Sector Perform and lowers the price target from $55 to $45.
Mizuho Maintains Buy on HCA Healthcare, Lowers Price Target to $210
Mizuho analyst Ann Hynes maintains HCA Healthcare (NYSE:HCA) with a Buy and lowers the price target from $260 to $210.
RBC Capital Maintains Sector Perform on General Mills, Raises Price Target to $68
RBC Capital analyst Nik Modi maintains General Mills (NYSE:GIS) with a Sector Perform and raises the price target from $66 to $68.
JP Morgan Maintains Overweight on Micron Technology, Lowers Price Target to $80
JP Morgan analyst Harlan Sur maintains Micron Technology (NASDAQ:MU) with a Overweight and lowers the price target from $96 to $80.
NRx Pharmaceuticals Announces FDA Declines Emergency Use Authorization For ZYESAMI For Subgroup Of Patients With Critical COVID-19 At Immediate Risk Of Death From Respiratory Failure Despite Treatment With Approved Therapy, Including Remdesivir
Focus is now on NRX-101 for Bipolar Depression with Suicidality
RADNOR, Pa., July 1, 2022 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (NASDAQ:NRXP), ("NRx Pharmaceuticals"), a clinical-stage